

Roberta Ricciarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3378827/publications.pdf>

Version: 2024-02-01

75
papers

4,557
citations

126708

33
h-index

98622

67
g-index

77
all docs

77
docs citations

77
times ranked

6397
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Glutathione in Cancer Progression and Chemoresistance. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-10.	1.9	886
2	Vitamin E Reduces the Uptake of Oxidized LDL by Inhibiting CD36 Scavenger Receptor Expression in Cultured Aortic Smooth Muscle Cells. <i>Circulation</i> , 2000, 102, 82-87.	1.6	273
3	Non-antioxidant molecular functions of Î±-tocopherol (vitamin E). <i>FEBS Letters</i> , 2002, 519, 8-10.	1.3	267
4	Î±-Tocopherol specifically inactivates cellular protein kinase C Î± by changing its phosphorylation state. <i>Biochemical Journal</i> , 1998, 334, 243-249.	1.7	254
5	The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. <i>Current Neuropharmacology</i> , 2017, 15, 926-935.	1.4	253
6	Vitamin E: protective role of a Janus molecule. <i>FASEB Journal</i> , 2001, 15, 2314-2325.	0.2	230
7	Age-dependent increase of collagenase expression can be reduced by Î±-tocopherol via protein kinase C inhibition. <i>Free Radical Biology and Medicine</i> , 1999, 27, 729-737.	1.3	167
8	GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. <i>British Journal of Pharmacology</i> , 2011, 164, 2054-2063.	2.7	128
9	Specific Cellular Responses to Î±-Tocopherol. <i>Journal of Nutrition</i> , 2000, 130, 1649-1652.	1.3	126
10	Vitamin E and neurodegenerative diseases. <i>Molecular Aspects of Medicine</i> , 2007, 28, 591-606.	2.7	96
11	Molecular basis of Î±-tocopherol control of smooth muscle cell proliferation. <i>BioFactors</i> , 1998, 7, 3-14.	2.6	95
12	The 80th Anniversary of Vitamin E: Beyond Its Antioxidant Properties. <i>Biological Chemistry</i> , 2002, 383, 457-65.	1.2	95
13	Cloning of novel human SEC14p-like proteins: ligand binding and functional properties. <i>Free Radical Biology and Medicine</i> , 2003, 34, 1458-1472.	1.3	78
14	Role of peroxisome proliferator-activated receptor Î³ in amyloid precursor protein processing and amyloid Î²-mediated cell death. <i>Biochemical Journal</i> , 2005, 391, 693-698.	1.7	78
15	Microarray Analysis in Alzheimer's Disease and Normal Aging. <i>IUBMB Life</i> , 2004, 56, 349-354.	1.5	77
16	Regulation of Recombinant PKCÎ± Activity by Protein Phosphatase 1 and Protein Phosphatase 2A. <i>Archives of Biochemistry and Biophysics</i> , 1998, 355, 197-200.	1.4	73
17	Î±-Tocopherol Induces Expression of Connective Tissue Growth Factor and Antagonizes Tumor Necrosis Factor-Î±-Mediated Downregulation in Human Smooth Muscle Cells. <i>Circulation Research</i> , 2003, 92, 104-110.	2.0	71
18	Vitamin E inhibits CD36 scavenger receptor expression in hypercholesterolemic rabbits. <i>Atherosclerosis</i> , 2006, 184, 15-20.	0.4	63

#	ARTICLE	IF	CITATIONS
19	Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 46320.	1.6	63
20	Nonantioxidant Functions of α -Tocopherol in Smooth Muscle Cells. <i>Journal of Nutrition</i> , 2001, 131, 378S-381S.	1.3	59
21	Amyloid- β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory. <i>Journal of Neuroscience</i> , 2017, 37, 6926-6937.	1.7	59
22	CD36 overexpression in human brain correlates with β -amyloid deposition but not with Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2004, 36, 1018-1024.	1.3	53
23	Regulatory effects of curcumin on lipid accumulation in monocytes/macrophages. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 833-840.	1.2	53
24	Troglitazone, a peroxisome proliferator-activated receptor- β agonist, decreases tau phosphorylation in CHOtau4R cells. <i>Journal of Neurochemistry</i> , 2006, 98, 1068-1077.	2.1	45
25	Characterization of three human sec14p-like proteins: α -Tocopherol transport activity and expression pattern in tissues. <i>Biochimie</i> , 2008, 90, 1703-1715.	1.3	44
26	N-Alkyl Carbazole Derivatives as New Tools for Alzheimer's Disease: Preliminary Studies. <i>Molecules</i> , 2014, 19, 9307-9317.	1.7	41
27	Cholesterol and Alzheimer's disease: A still poorly understood correlation. <i>IUBMB Life</i> , 2012, 64, 931-935.	1.5	40
28	Modulation of cAMP levels by high-fat diet and curcumin and regulatory effects on CD36/FAT scavenger receptor/fatty acids transporter gene expression. <i>BioFactors</i> , 2017, 43, 42-53.	2.6	40
29	Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma. <i>Oncotarget</i> , 2016, 7, 70715-70737.	0.8	40
30	Novel 5' Exon of Scavenger Receptor CD36 Is Expressed in Cultured Human Vascular Smooth Muscle Cells and Atherosclerotic Plaques. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 412-417.	1.1	38
31	CD36 overexpression in ritonavir-treated THP-1 cells is reversed by α -tocopherol. <i>Free Radical Biology and Medicine</i> , 2005, 38, 1047-1056.	1.3	36
32	cAMP, cGMP and Amyloid β : Three Ideal Partners for Memory Formation. <i>Trends in Neurosciences</i> , 2018, 41, 255-266.	4.2	36
33	Scavenger Receptors and Modified Lipoproteins: Fatal Attractions?. <i>IUBMB Life</i> , 2000, 49, 397-403.	1.5	35
34	Cholesterol and Amyloid- β : Evidence for a Cross-Talk between Astrocytes and Neuronal Cells. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 645-653.	1.2	35
35	A novel mechanism for cyclic adenosine monophosphate-mediated memory formation: Role of amyloid beta. <i>Annals of Neurology</i> , 2014, 75, 602-607.	2.8	32
36	New insights into selective PDE4D inhibitors: 3-(Cyclopentylloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 82-102.	2.6	31

#	ARTICLE	IF	CITATIONS
37	Vitamin E mediated response of smooth muscle cell to oxidant stress. <i>Diabetes Research and Clinical Practice</i> , 1999, 45, 191-198.	1.1	29
38	Vitamin E 80th Anniversary: A Double Life, Not Only Fighting Radicals. <i>IUBMB Life</i> , 2001, 52, 71-76.	1.5	29
39	PKC δ Sensitizes Neuroblastoma Cells to L-Buthionine-Sulfoximine and Etoposide Inducing Reactive Oxygen Species Overproduction and DNA Damage. <i>PLoS ONE</i> , 2011, 6, e14661.	1.1	28
40	Oxysterol mixture and, in particular, 27 α -hydroxycholesterol drive M2 polarization of human macrophages. <i>BioFactors</i> , 2016, 42, 80-92.	2.6	26
41	Phosphodiesterase 4D: an enzyme to remember. <i>British Journal of Pharmacology</i> , 2015, 172, 4785-4789.	2.7	25
42	Protein Kinase C: An Attractive Target for Cancer Therapy. <i>Cancers</i> , 2011, 3, 531-567.	1.7	24
43	Presynaptic GLP α 1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus. <i>BioFactors</i> , 2018, 44, 148-157.	2.6	24
44	Scavenger receptor regulation and atherosclerosis. <i>BioFactors</i> , 2000, 11, 189-200.	2.6	23
45	Cyclic adenosine monophosphate as an endogenous modulator of the amyloid β precursor protein metabolism. <i>IUBMB Life</i> , 2013, 65, 127-133.	1.5	21
46	Amyloid β : Walking on the dark side of the moon. <i>Mechanisms of Ageing and Development</i> , 2015, 152, 1-4.	2.2	20
47	Synthesis, Biological Evaluation, and Molecular Modeling of New 3-(Cyclopentyloxy)-4-methoxybenzaldehyde <i>O</i> -(2-(2,6-Dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) Related Phosphodiesterase 4D (PDE4D) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7061-7072.	2.9	17
48	Oxidized LDLs as Signaling Molecules. <i>Antioxidants</i> , 2021, 10, 1184.	2.2	17
49	Effects of ethanol metabolism on PKC activity in isolated rat hepatocytes. <i>Chemico-Biological Interactions</i> , 1996, 100, 155-163.	1.7	16
50	Modulation of Proteasome Activity by Vitamin E in THP-1 Monocytes. <i>IUBMB Life</i> , 2007, 59, 771-780.	1.5	14
51	Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3426-3435.	1.4	13
52	Isoelectric Point Mobility Shift Assay for Rapid Screening of Charged and Uncharged Ligands Bound to Proteins. <i>IUBMB Life</i> , 2003, 55, 103-107.	1.5	12
53	HIV Protease Inhibitors-induced Atherosclerosis: Prevention by α -Tocopherol. <i>IUBMB Life</i> , 2004, 56, 629-631.	1.5	12
54	Evidence against the overexpression of APP in down syndrome. <i>IUBMB Life</i> , 2006, 58, 103-106.	1.5	11

#	ARTICLE	IF	CITATIONS
55	DNA oxidative damage of neoplastic rat liver lesions. <i>Oncology Reports</i> , 2010, 23, 1241-6.	1.2	11
56	Memory Enhancers for Alzheimer's Dementia: Focus on cGMP. <i>Pharmaceuticals</i> , 2021, 14, 61.	1.7	11
57	Downregulation of myosin II-B by siRNA alters the subcellular localization of the amyloid precursor protein and increases amyloid- β deposition in N2a cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 362, 633-638.	1.0	10
58	PDE4D inhibitors: A potential strategy for the treatment of memory impairment?. <i>Neuropharmacology</i> , 2014, 85, 290-292.	2.0	10
59	Reduction of senescence-associated beta-galactosidase activity by vitamin E in human fibroblasts depends on subjects' age and cell passage number. <i>BioFactors</i> , 2020, 46, 665-674.	2.6	9
60	3-Aminobenzamide inhibition of protein kinase C at a cellular level. <i>FEBS Letters</i> , 1998, 431, 465-467.	1.3	8
61	Alternative splicing and gene polymorphism of the human TAP3/SEC14L4 gene. <i>Molecular Biology Reports</i> , 2010, 37, 3503-3508.	1.0	8
62	cGMP favors the interaction between APP and BACE1 by inhibiting Rab5 GTPase activity. <i>Scientific Reports</i> , 2020, 10, 1358.	1.6	8
63	Protein kinase C-dependent secretory processing of the amyloid precursor protein is mediated by phosphorylation of myosin II. <i>FASEB Journal</i> , 2009, 23, 1246-1251.	0.2	7
64	Investigating the amyloid-beta enhancing effect of cGMP in neuro2a cells. <i>Mechanisms of Ageing and Development</i> , 2017, 166, 1-5.	2.2	6
65	Evaluating the role of hnRNP and FMRP in the cAMP-induced APP metabolism. <i>BioFactors</i> , 2015, 41, 121-126.	2.6	5
66	Protein kinase G phosphorylates the Alzheimer's disease-associated tau protein at distinct Ser/Thr sites. <i>BioFactors</i> , 2021, 47, 126-134.	2.6	5
67	Selective inhibition of phosphodiesterase 4D increases tau phosphorylation at Ser214 residue. <i>BioFactors</i> , 2022, , .	2.6	3
68	In vitro effect of PPAR- β Pro12Ala polymorphism on the deposition of Alzheimer's amyloid- β peptides. <i>Brain Research</i> , 2007, 1173, 1-5.	1.1	2
69	A New Bistable Switch Model of Alzheimer's Disease Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7061.	1.8	2
70	Evaluating the Correlation between Alzheimer's Amyloid- β Peptides and Glaucoma in Human Aqueous Humor. <i>Translational Vision Science and Technology</i> , 2020, 9, 21.	1.1	1
71	Protein kinase C inactivation by Fenton's-reaction at discrete CU binding sites. <i>IUBMB Life</i> , 1996, 40, 285-293.	1.5	0
72	Downregulation of myosin II by siRNA alters the subcellular localization of APP and increases A β deposition in N2a cells. <i>FASEB Journal</i> , 2007, 21, .	0.2	0

#	ARTICLE	IF	CITATIONS
73	Involvement of myosin II and protein kinase C in the processing of APP. FASEB Journal, 2008, 22, 585-585.	0.2	0
74	p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment. FASEB Journal, 2013, 27, 1088.14.	0.2	0
75	Stimulation of the amyloid precursor protein metabolism by cAMP. FASEB Journal, 2013, 27, 873.18.	0.2	0